Ra Medical Systems Regains Compliance with NYSE American Continued Listing Standards

Rhea-AI Summary

Ra Medical Systems (NYSE American: RMED) has announced compliance with the NYSE American's continued listing standards, resolving previous deficiencies related to its stock price. As of December 9, 2022, the Company's compliance indicator will be removed, and it will no longer appear on the NYSE’s list of noncompliant issuers. Ra Medical is known for its patented excimer laser platform aimed at treating vascular immune-mediated inflammatory diseases, particularly through its DABRA Excimer Laser System for peripheral artery disease.

Positive

• Ra Medical has regained compliance with the NYSE American's continued listing standards.
• The compliance indicator will be removed as of December 9, 2022.

Negative

• None.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces that it has received notification from the NYSE American LLC (“NYSE American”) that the Company has regained compliance with the NYSE American’s continued listing standard. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide.

In the notification, the NYSE American informed the Company that as of December 9, 2022, the below compliance (“.BS) indicator will no longer be disseminated and the Company has been removed from the NYSE American noncompliant issuers on the NYSE American’s website.

About Ra Medical Systems

Ra Medical Systems, Inc. is a medical device company that owns intellectual property related to an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases. Its excimer laser and single-use catheter system, together referred to as the DABRA Excimer Laser System, is used as a tool in the treatment of peripheral artery disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214006025/en/

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

Source: Ra Medical Systems, Inc.

FAQ

What compliance milestone has Ra Medical Systems (RMED) recently achieved?

Ra Medical Systems has regained compliance with the NYSE American's continued listing standards.

When will Ra Medical Systems be removed from the NYSE American's noncompliant issuers list?

Ra Medical Systems will be removed from the NYSE American's noncompliant issuers list as of December 9, 2022.

What technology does Ra Medical Systems focus on?

Ra Medical Systems specializes in an excimer laser platform used to treat vascular immune-mediated inflammatory diseases.

What is the significance of the DABRA Excimer Laser System?

The DABRA Excimer Laser System is used in the treatment of peripheral artery disease.